First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
NCT07679061
·
clinicaltrials.gov ↗
RECRUITING
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
COMBINATION_PRODUCT:
Nivolumab plus ipilimumab
Sponsor
Bristol-Myers Squibb
Collaborators
[object Object]